24/2/2025, 9:53:03 am

Lupin’s Somerset Facility Receives USFDA EIR

Lupin Ltd. received an EIR from the USFDA for its Somerset, New Jersey facility after an inspection from January 27 to 31, 2025. The EIR confirms compliance with cGMP and regulatory standards, enabling continued drug manufacturing and US market access. Lupin, a top 10 global pharma company operating in 149 countries, strengthens its compliance credentials with this milestone.